Cisplatin (cis-diamminedichloroplatinum (II)) is the oldest known chemotherapeutic agent.
Since the identification of its anti-tumour activity, it earned a remarkable place as a treatment …

DNA repair targeted therapeutics is a promising precision medicine strategy in cancer. The
development and clinical use of PARP inhibitors has transformed lives for many patients …

Ovarian cancer (OC) is a lethal gynecologic malignancy, with modest responses to CPI.
Engagement of additional immune arms, such as NK cells, may be of value. We focused on …

The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of
the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we …

Poly (ADP-ribose) ylation or PARylation by PAR polymerase 1 (PARP1) and dePARylation
by poly (ADP-ribose) glycohydrolase (PARG) are equally important for the dynamic …

Platinum resistance is a clinical challenge in ovarian cancer. Platinating agents induce DNA
damage which activate Mre11 nuclease directed DNA damage signalling and response …

DNA damage signaling response and repair (DDR) is a critical defense mechanism against
genomic instability. Impaired DNA repair capacity is an important risk factor for cancer …

The reasonable design of binuclear or multinuclear metal complexes has demonstrated their
potential advantages in the anticancer field. Herein, three heterobimetallic Ir (III)–Re (I) …

ABSTRACT DNA polymerase beta (Pol β) is a 39 kD vertebrate polymerase that lacks
proofreading ability, yet still maintains a moderate fidelity of DNA synthesis. Pol β is a key …

DNA Polymerase β (Polβ) is a key enzyme in base excision repair (BER), which is very
important in maintaining the stability and integrity of the genome. Mutant Polβ is closely …